GULMEZ A.DIKILITAS M.ELKIRAN E.T.HARPUTLUOGLU H.2024-08-042024-08-0420212468-2942https://doi.org/10.1016/j.ctarc.2021.100366https://hdl.handle.net/11616/92023Sunitinib malate is a multitargeted oral tyrosine kinase inhibitor (TKI) which is used in treatment of metastatic renal cell carcinoma with side effects such as diarrhea, mucositis, asthenia and myelosuppression. Serious toxicity associated with sunitinib is a rare situation. However; there are few cases reported in the literature. As a result of the inhibition that is caused by sunitinib malate agent at the receptor level, vascular endothelial growth factor (VEGF) level increases. These increased VEGF levels are considered to having a positive contribution on neurological side effects. Neurotoxicity that is related with the usage of sunitinib malate for two weeks will be presented in this case report. © 2021 The Author(s)eninfo:eu-repo/semantics/openAccessNeurotoxicityRenal cell cancerTyrosine Kinase InhibitorArticle273381218010.1016/j.ctarc.2021.1003662-s2.0-85104956589Q3